|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Department of Veterans Affairs |
|---|---|
| Collaborators: |
Agency for Healthcare Research and Quality (AHRQ) National Cancer Institute (NCI) |
| Information provided by: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00007644 |
Purpose
Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective. Expectant management does not offer potential cure. However, it provides palliative therapy for symptomatic or metastatic disease progression, avoids potentially excessive and morbid interventions in asymptomatic patients, and emphasizes management approaches for focus on relieving symptoms while minimizing therapeutic complications.
The primary objective of this study is to determine which of two strategies is superior for the management of clinically localized CAP: 1) radical prostatectomy with early aggressive intervention for disease persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of symptomatic or metastatic disease progression. Outcomes include total mortality, CAP mortality, disease free and progression free survival, morbidity, quality of life, and cost effectiveness.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostate Cancer |
Procedure: Radical prostatectomy Procedure: Expectant management with palliative therapy |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer |
| Enrollment: | 731 |
| Study Start Date: | June 1994 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Radical Prostatectomy
|
Procedure: Radical prostatectomy
Surgical removal of the prostate
|
|
2: No Intervention
Watchful Waiting
|
Procedure: Expectant management with palliative therapy
palliative therapy for symptomatic or metastatic disease progression
|
Primary Hypothesis: To determine whether radical prostatectomy or expectant management is more effective in reducing mortality and extending life.
Secondary Hypothesis: To determine which treatment strategy is superior in terms of prostate specific cancer mortality, quality of life, occurrence or recurrence of symptoms and need for cancer treatment.
Intervention: 1) Radical prostatectomy, plus intervention for evidence of disease persistence or recurrence, 2) Expectant management with palliative therapy reserved for symptomatic or metastatic disease progression.
Primary Outcomes: All cause mortality.
Study Abstract: Cancer of the prostate (CAP) is the most common nondermatologic and the second most frequent cause of cancer deaths in men. No cure is currently possible for disseminated disease. Cancer confined to the prostate is believed to be curable, with the most frequently recommended therapy being surgical extirpation of the tumor with radical prostatectomy. However, despite increasing cancer detection and aggressive surgical treatment, population-based mortality rates from prostate cancer have not decreased, neither nationally nor in states with high rates of radical prostatectomy. Existing evidence does not demonstrate the superiority of this procedure compared to expectant management in the treatment of localized prostate cancer. Data from case series suggest that either treatment approach provides equivalent all-cause as well as prostate cancer specific mortality. The only randomized trial was limited by a small sample size but the results favored expectant management.
Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective. Expectant management does not offer potential cure. However, it provides palliative therapy for symptomatic or metastatic disease progression, avoids potentially excessive and morbid interventions in asymptomatic patients, and emphasizes management approaches for focus on relieving symptoms while minimizing therapeutic complications.
The primary objective of this study is to determine which of two strategies is superior for the management of clinically localized CAP: 1) radical prostatectomy with early aggressive intervention for disease persistence or recurrence, 2) expectant management with reservation of therapy for palliative treatment of symptomatic or metastatic disease progression. Outcomes include total mortality, CAP mortality, disease free and progression free survival, morbidity, quality of life, and cost effectiveness.
Eligibility| Ages Eligible for Study: | up to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Hide Study Locations| United States, Alabama | |
| VA Medical Center, Birmingham | |
| Birmingham, Alabama, United States, 35233 | |
| United States, Arkansas | |
| Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock | |
| No. Little Rock, Arkansas, United States, 72114-1706 | |
| United States, California | |
| VA Medical Center, Long Beach | |
| Long Beach, California, United States, 90822 | |
| VA Medical Center, San Francisco | |
| San Francisco, California, United States, 94121 | |
| VA Greater Los Angeles HCS, Sepulveda | |
| Sepulveda, California, United States, 91343 | |
| United States, Florida | |
| James A. Haley Veterans Hospital, Tampa | |
| Tampa, Florida, United States, 33612 | |
| United States, Idaho | |
| VA Medical Center, Boise | |
| Boise, Idaho, United States, 83702 | |
| United States, Illinois | |
| Jesse Brown VAMC (WestSide Division) | |
| Chicago, Illinois, United States, 60612 | |
| United States, Indiana | |
| Richard Roudebush VA Medical Center, Indianapolis | |
| Indianapolis, Indiana, United States, 46202-2884 | |
| United States, Iowa | |
| VA Medical Center, Iowa City | |
| Iowa City, Iowa, United States, 52246-2208 | |
| United States, Kentucky | |
| VA Medical Center, Lexington | |
| Lexington, Kentucky, United States, 40502 | |
| United States, Louisiana | |
| Overton Brooks VA Medical Center, Shreveport | |
| Shreveport, Louisiana, United States, 71101 | |
| United States, Michigan | |
| VA Ann Arbor Healthcare System | |
| Ann Arbor, Michigan, United States, 48113 | |
| United States, Minnesota | |
| Minneapolis VA Medical Center | |
| Minneapolis, Minnesota, United States, 55417 | |
| United States, New Jersey | |
| VA New Jersey Health Care System, East Orange | |
| East Orange, New Jersey, United States, 07018 | |
| United States, New York | |
| VA Stratton Medical Center, Albany | |
| Albany, New York, United States, 12208 | |
| VA Medical Center, Bronx | |
| Bronx, New York, United States, 10468 | |
| New York Harbor Health Care System, Brooklyn | |
| Brooklyn, New York, United States, 11209 | |
| VA Western New York Healthcare System at Buffalo | |
| Buffalo, New York, United States, 14215 | |
| VA Medical Center, Syracuse | |
| Syracuse, New York, United States, 13210 | |
| United States, Oklahoma | |
| VA Medical Center, Oklahoma City | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Oregon | |
| VA Medical Center, Portland | |
| Portland, Oregon, United States, 97201 | |
| United States, Pennsylvania | |
| VA Pittsburgh Health Care System | |
| Pittsburgh, Pennsylvania, United States, 15240 | |
| United States, Rhode Island | |
| VA Medical Center, Providence | |
| Providence, Rhode Island, United States, 02908 | |
| United States, Tennessee | |
| VA Medical Center, Memphis | |
| Memphis, Tennessee, United States, 38104 | |
| United States, Texas | |
| VA North Texas Health Care System, Dallas | |
| Dallas, Texas, United States, 75216 | |
| Central Texas Veterans Health Care System | |
| Temple, Texas, United States, 76504 | |
| United States, Virginia | |
| VA Medical Center, Hampton | |
| Hampton, Virginia, United States, 23667 | |
| United States, Washington | |
| VA Puget Sound Health Care System, Seattle | |
| Seattle, Washington, United States, 98108 | |
| United States, West Virginia | |
| VA Medical Center, Clarksburg | |
| Clarksburg, West Virginia, United States, 26301 | |
| United States, Wisconsin | |
| Wlliam S. Middleton Memorial Veterans Hospital, Madison | |
| Madison, Wisconsin, United States, 53705 | |
| Study Chair: | Timothy James Wilt, MD MPH | Minneapolis Veterans Affairs Medical Center |
More Information
| Responsible Party: | Department of Veterans Affairs ( Wilt, Timothy - Study Chair ) |
| Study ID Numbers: | 407 |
| Study First Received: | December 29, 2000 |
| Last Updated: | October 8, 2009 |
| ClinicalTrials.gov Identifier: | NCT00007644 History of Changes |
| Health Authority: | United States: Federal Government |
|
cancer of the prostate (CAP) cancer treatment chronic diseases expectant management |
genitourinary prostate prostate specific cancer mortality radical prostatectomy |
|
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |